Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have been approved for management of locally advanced and metastatic bladder cancer, but low response rates in patients (20–30%) urge for better understanding of mechanisms underlying BC immune escape (reviewed in [6]). Here, CD274 is linked to urinary bladder carcinoma.